V

accine giant Sanofi Pasteur has quietly pulled the plug on its Zika vaccine project, a move that underscores how difficult it may be at this stage to develop a vaccine against the virus.

The company announced the move in a statement posted on its website at 3 p.m. Friday, pointing to a decision by a federal funding body to scale back spending on Zika-related research. Sanofi said BARDA — the Biomedical Advanced Research and Development Authority, an arm of the Department of Health and Human Services — informed the company in mid-August that it was reducing its financial assistance for Sanofi’s Zika vaccine project.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy